Patents by Inventor Andreas Koblet
Andreas Koblet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240002393Abstract: Compounds having the general formula (I) wherein R1, R2, R3, R4, R5 and X are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: July 20, 2023Publication date: January 4, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Frédéric KNOFLACH, Andreas KOBLET, Eoin Cornelius O'CONNOR, Andres Miguel OLIVARES MORALES, Michael REUTLINGER, Valerie RUNTZ-SCHMITT, Jaclyn Ivy WAMSTEEKER CUSULIN, Nicolas ZORN
-
Patent number: 11840528Abstract: The invention provides novel compounds having the general formula (I) or (II) wherein R2, R3, R5, R99, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: December 11, 2020Date of Patent: December 12, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Giuseppe Cecere, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Andres Miguel Olivares Morales, Angélique Patiny-Adam, Emmanuel Pinard, Valerie Runtz-Schmitt, Sandra Steiner
-
Patent number: 11739095Abstract: Compounds having the general formula (I) wherein R1, R2, R3, R4, R5 and X are as described herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: March 30, 2021Date of Patent: August 29, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Giuseppe Cecere, Luca Gobbi, Maria-Clemencia Hernandez, Frédéric Knoflach, Andreas Koblet, Eoin Cornelius O'Connor, Andres Miguel Olivares Morales, Michael Reutlinger, Valerie Runtz-Schmitt, Jaclyn Ivy Wamsteeker Cusulin, Nicolas Zorn
-
Publication number: 20230141603Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R3, R4, R5 and X are as described herein, compositions including the compounds and methods of using the compounds for treatment of CNS disorders.Type: ApplicationFiled: October 18, 2022Publication date: May 11, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Frédéric KNOFLACH, Andreas KOBLET, Eoin Cornelius O'CONNOR, Andres Miguel OLIVARES MORALES, Valerie RUNTZ-SCHMITT, Jaclyn WAMSTEEKER CUSULIN, Nicolas ZORN
-
Publication number: 20230135093Abstract: The invention provides compounds having the general formula (I) or (II) wherein R1, R2, R3, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: November 11, 2022Publication date: May 4, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Giuseppe CECERE, Guillaume DÉCORET, Katrin GROEBKE ZBINDEN, Maria-Clemencia HERNANDEZ, Henner KNUST, Andreas KOBLET, Andres Miguel OLIVARES MORALES, Emmanuel PINARD, Valerie RUNTZ-SCHMITT
-
Publication number: 20230136326Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.Type: ApplicationFiled: September 28, 2022Publication date: May 4, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Bjoern BARTELS, Giuseppe CECERE, Guido GALLEY, Luca GOBBI, Maria-Clemencia HERNANDEZ, Andreas KOBLET, Andrés Miguel OLIVARES MORALES, Angélique PATINY-ADAM, Valerie RUNTZ-SCHMITT
-
Publication number: 20230109111Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.Type: ApplicationFiled: September 23, 2022Publication date: April 6, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Giuseppe CECERE, Guido GALLEY, Luca GOBBI, Maria-Clemencia HERNANDEZ, Andreas KOBLET, Andrés Miguel OLIVARES MORALES, Valerie RUNTZ-SCHMITT
-
Publication number: 20220411415Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: July 16, 2021Publication date: December 29, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Bernd BUETTELMANN, Giuseppe Cecere, Bernhard Fasching, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Emmanuel Pinard, Andrew Thomas
-
Publication number: 20210309664Abstract: Compounds having the general formula (I) wherein R1, R2, R3, R4, R5 and X are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: March 30, 2021Publication date: October 7, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Frédéric KNOFLACH, Andreas KOBLET, Eoin Cornelius O'CONNOR, Andres Miguel OLIVARES MORALES, Michael REUTLINGER, Valerie RUNTZ-SCHMITT, Jaclyn Ivy WAMSTEEKER CUSULIN, Nicolas ZORN
-
Patent number: 11091471Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: June 5, 2019Date of Patent: August 17, 2021Assignee: Hoffmann-La Roche Inc.Inventors: Bernd Buettelmann, Giuseppe Cecere, Bernhard Fasching, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Emmanuel Pinard, Andrew Thomas
-
Publication number: 20210094945Abstract: The invention provides novel compounds having the general formula (I) or (II) wherein R2, R3, R5, R99, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: December 11, 2020Publication date: April 1, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Giuseppe Cecere, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Andres Miguel Olivares Morales, Angélique Patiny-Adam, Emmanuel Pinard, Valerie Runtz-Schmitt, Sandra Steiner
-
Publication number: 20190300516Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: June 5, 2019Publication date: October 3, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Bernd BUETTELMANN, Giuseppe CECERE, Bernhard FASCHING, Katrin GROEBKE ZBINDEN, Maria-Clemencia HERNANDEZ, Henner KNUST, Andreas KOBLET, Emmanuel PINARD, Andrew THOMAS
-
Patent number: 9346786Abstract: The present application relates to compounds of formula wherein R1, R2, R3, R4, and n are defined herein or to a pharmaceutically active salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).Type: GrantFiled: March 13, 2013Date of Patent: May 24, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Henner Knust, Andreas Koblet, Matthias Nettekoven, Hasane Ratni, Claus Riemer, Walter Vifian
-
Patent number: 9226916Abstract: The present invention relates to compounds of formula wherein R1, R2, R3, R4, Z, and n are as defined herein or to a pharmaceutically active salt thereof. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).Type: GrantFiled: February 28, 2013Date of Patent: January 5, 2016Assignee: HOFFMANN-LA ROCHE INC.Inventors: Henner Knust, Andreas Koblet, Matthias Nettekoven, Hasane Ratni, Claus Riemer, Walter Vifian
-
Publication number: 20150157739Abstract: The invention relates to imidazo[2,1-b]thiazol-3-one derivatives of formula wherein the variables are defined herein, or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. It has been shown that the present compounds may be used for binding and imaging tau aggregates and related b-sheet aggregates including besides others beta-amyloid aggregates or alpha-synuclein aggregates, especially for use in binding and imaging tau aggregates in Alzheimer's patients.Type: ApplicationFiled: February 13, 2015Publication date: June 11, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Luca Gobbi, Henner Knust, Andreas Koblet
-
Patent number: 8404708Abstract: The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula wherein the substituents are as described herein or a pharmaceutically active acid-addition salt thereof. In particular, the invention provides methods for treating both positive and negative symptoms of schizophrenia through dual inhibition of NK1 and NK3 receptors. The invention also provides novel compounds with formula I and methods for preparing compounds of the invention.Type: GrantFiled: March 31, 2011Date of Patent: March 26, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Torsten Hoffmann, Andreas Koblet, Jens-Uwe Peters, Patrick Schnider, Andrew Sleight, Heinz Stadler
-
Patent number: 8404679Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, Ar and n are as defined herein and pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers or tautomeric forms thereof. The compounds can be used for the treatment of depression, anxiety or schizophrenia.Type: GrantFiled: April 23, 2012Date of Patent: March 26, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Caterina Bissantz, Philippe Jablonski, Henner Knust, Andreas Koblet, Anja Limberg, Matthias Nettekoven, Hasane Ratni, Claus Riemer
-
Publication number: 20120208803Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, Ar and n are as defined herein and pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers or tautomeric forms thereof. The compounds can be used for the treatment of depression, anxiety or schizophrenia.Type: ApplicationFiled: April 23, 2012Publication date: August 16, 2012Inventors: Caterina Bissantz, Philippe Jablonski, Henner Knust, Andreas Koblet, Anja Limberg, Matthias Nettekoven, Hasane Ratni, Claus Riemer
-
Publication number: 20110178055Abstract: The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula wherein the substituents are as described herein or a pharmaceutically active acid-addition salt thereof. In particular, the invention provides methods for treating both positive and negative symptoms of schizophrenia through dual inhibition of NK1 and NK3 receptors. The invention also provides novel compounds with formula I and methods for preparing compounds of the invention.Type: ApplicationFiled: March 31, 2011Publication date: July 21, 2011Inventors: Torsten Hoffmann, Andreas Koblet, Jens-Uwe Peters, Patrick Schnider, Andrew Sleight, Heinz Stadler
-
Publication number: 20110152233Abstract: The present application relates to compounds of formula wherein R1, R2, R3, R4, and n are defined herein or to a pharmaceutically active salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).Type: ApplicationFiled: December 10, 2010Publication date: June 23, 2011Inventors: Henner Knust, Andreas Koblet, Matthias Nettekoven, Hasane Ratni, Claus Riemer, Walter Vifian